Inmagene Biopharmaceuticals

IMA · Nasdaq · United States

Share price · IMA

$3.81-1.87 (-32.92%) 3M

close as of 2026-11-18 · 24h delayed · vol 6K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IMA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026+21.9%
  2. 23 Oct 2026+4.3%
  3. 8 Oct 2026-7.6%
  4. 12 Aug 2026+6.8%

    Nothing announced by IMA that day or the session before.

  5. 23 Jul 2026-6.7%
  6. 20 Jul 2026+6.5%
  7. 16 Jul 2026-9.3%
  8. 8 May 2026-10.5%
  9. 13 Apr 2026+23.4%
  10. 6 Apr 2026-8.5%

    Nothing announced by IMA that day or the session before.

Share of unusual movement by asset

For each asset, the share of IMA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Olevaprubart
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—18%
Sessions with no dated event—82%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
OX40Monoclonal antibody
Atopic Dermatitis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
OlevaprubartPhase 2Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Est. primary completion 2027-12 · NCT07037901 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
OlevaprubartPhase 2Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Est. primary completion 2028-03 · NCT07734415 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$11M$85M+ $42M short-term inv.$16M-$9.5M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$6.7M$95M+ $41M short-term inv.$10M-$9.1M operating cash flowreport ↗
2026-Q1—$6.0M$117M$11Mreport ↗
2025-Q3—$16M$103M+ $39M short-term inv.$25M-$27M operating cash flowreport ↗
2025-Q2—$4.0M$59M+ $37M short-term inv.$2.8M-$3.4M operating cash flowreport ↗
2025-Q1$0.8M$3.7M$38M+ $77M short-term inv.$8.6M-$11M operating cash flowreport ↗
2024-Q3$3.5M$6.8M$46M+ $93M short-term inv.$10M-$8.9M operating cash flowreport ↗
2024-Q2—$9.8M$46M+ $101M short-term inv.$14M-$13M operating cash flowreport ↗
2024-Q1—$9.7M$54M+ $105M short-term inv.$16M-$18M operating cash flowreport ↗
2023-Q3$1.2M$15M$123M+ $76M short-term inv.$17M-$20M operating cash flowreport ↗
2023-Q2$2.0M$15M$72M+ $86M short-term inv.$17M-$18M operating cash flowreport ↗
2023-Q1$5.3M$16M$30M+ $108M short-term inv.$14M-$20M operating cash flowreport ↗
2022-Q3$6.4M$19M$68M+ $107M short-term inv.$17M-$17M operating cash flowreport ↗
2022-Q2$0.4M$15M$49M+ $144M short-term inv.$20M-$19M operating cash flowreport ↗
2022-Q1$3.4M$14M$48M+ $166M short-term inv.$17M-$20M operating cash flowreport ↗
2021-Q3$3.8M$13M$247M$15Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.8M$29M$95M+ $41M short-term inv.$11M-$48M operating cash flowreport ↗

Inmagene Biopharmaceuticals reported revenue of $0.8M, down 77.1% YoY, R&D spend of $28.53M, down 7.6% YoY, cash and equivalents of $94.53M, and a net loss of $45.35M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.5M$31M$40M+ $85M short-term inv.$12M-$46M operating cash flowreport ↗
2023-FY$9.2M$60M$121M+ $56M short-term inv.$17M-$80M operating cash flowreport ↗
2022-FY$16M$64M$61M+ $97M short-term inv.$17M-$74M operating cash flowreport ↗
2021-FY$31M$47M$233M$8.5M-$60M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($96K), 2 sales ($17K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-14Grant-Huerta Yanina · Chief Financial OfficerAward / grant65,000——Form 4
2026-08-14Yarema Kristin · director, Chief Executive OfficerAward / grant254,800——Form 4
2026-08-14Grant-Huerta Yanina · Chief Financial OfficerAward / grant39,000——Form 4
2026-08-14Yarema Kristin · director, Chief Executive OfficerAward / grant (derivative)137,200——Form 4
2026-08-14Grant-Huerta Yanina · Chief Financial OfficerAward / grant (derivative)56,000——Form 4
2026-08-14Yarema Kristin · director, Chief Executive OfficerAward / grant (derivative)250,000——Form 4
2026-07-25Yarema Kristin · director, Chief Executive OfficerOption exercise38,376——Form 4
2026-07-25Yarema Kristin · director, Chief Executive OfficerOther (see filing)115,129——Form 4